Are We Heading Toward a Recession?
Fears of a recession in 2025 grew at the end…
Buy
65
GHRS Quote, Financials, Valuation and Earnings
Last price:
$10.43
Seasonality move
:
23.28%
Day range:
$10.38 - $11.22
52-week range:
$6.00 - $20.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.60x
Volume:
70.5K
Avg. volume:
178.6K
1-year change:
-13.43%
Market cap:
$643.9M
Revenue:
--
EPS (TTM):
-$0.75
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GHRS
GH Research PLC
|
-- | -$0.20 | -- | -33.33% | $34.83 |
|
ITRM
Iterum Therapeutics PLC
|
-- | -$0.24 | -- | -49.47% | $7.00 |
|
JAZZ
Jazz Pharmaceuticals PLC
|
$983.8M | $4.66 | 3.11% | -28.31% | $184.00 |
|
MNMD
Mind Medicine
|
-- | -$0.37 | -- | -11.54% | $24.50 |
|
MURA
Mural Oncology PLC
|
-- | -$2.04 | -- | -9.51% | $5.00 |
|
PRTA
Prothena Corp PLC
|
$8.2M | -$1.03 | -86.45% | -23.01% | $49.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GHRS
GH Research PLC
|
$10.38 | $34.83 | $643.9M | -- | $0.00 | 0% | -- |
|
ITRM
Iterum Therapeutics PLC
|
$1.02 | $7.00 | $35.3M | -- | $0.00 | 0% | 29.06x |
|
JAZZ
Jazz Pharmaceuticals PLC
|
$97.78 | $184.00 | $6B | 13.04x | $0.00 | 0% | 1.54x |
|
MNMD
Mind Medicine
|
$6.15 | $24.50 | $464.6M | -- | $0.00 | 0% | -- |
|
MURA
Mural Oncology PLC
|
$2.63 | $5.00 | $45.3M | -- | $0.00 | 0% | -- |
|
PRTA
Prothena Corp PLC
|
$7.43 | $49.25 | $399.9M | -- | $0.00 | 0% | 2.92x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GHRS
GH Research PLC
|
-- | 1.295 | -- | -- |
|
ITRM
Iterum Therapeutics PLC
|
-- | 2.585 | -- | -- |
|
JAZZ
Jazz Pharmaceuticals PLC
|
56.25% | 0.854 | 70.16% | 2.64x |
|
MNMD
Mind Medicine
|
-- | 0.968 | -- | -- |
|
MURA
Mural Oncology PLC
|
-- | 2.733 | -- | -- |
|
PRTA
Prothena Corp PLC
|
-- | 1.383 | -- | 8.62x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GHRS
GH Research PLC
|
-- | -$12.9M | -- | -- | -- | -$10.5M |
|
ITRM
Iterum Therapeutics PLC
|
-- | -$3.7M | -- | -- | -- | -$4.3M |
|
JAZZ
Jazz Pharmaceuticals PLC
|
$793.2M | -$55.9M | 4.93% | 12.12% | -6.25% | $390.9M |
|
MNMD
Mind Medicine
|
-- | -$32.2M | -- | -- | -- | -$29.4M |
|
MURA
Mural Oncology PLC
|
-- | -$35.9M | -- | -- | -- | -$31.8M |
|
PRTA
Prothena Corp PLC
|
-- | -$65.6M | -21.68% | -21.68% | -2318.99% | -$53.4M |
GH Research PLC vs. Competitors
-
Which has Higher Returns GHRS or ITRM?
Iterum Therapeutics PLC has a net margin of -- compared to GH Research PLC's net margin of --. GH Research PLC's return on equity of -- beat Iterum Therapeutics PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GHRSGH Research PLC-- -$0.17 -- ITRMIterum Therapeutics PLC-- -$0.25 -- -
What do Analysts Say About GHRS or ITRM?
GH Research PLC has a consensus price target of $34.83, signalling upside risk potential of 235.58%. On the other hand Iterum Therapeutics PLC has an analysts' consensus of $7.00 which suggests that it could grow by 586.28%. Given that Iterum Therapeutics PLC has higher upside potential than GH Research PLC, analysts believe Iterum Therapeutics PLC is more attractive than GH Research PLC.
Company Buy Ratings Hold Ratings Sell Ratings GHRSGH Research PLC5 0 0 ITRMIterum Therapeutics PLC0 0 0 -
Is GHRS or ITRM More Risky?
GH Research PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Iterum Therapeutics PLC has a beta of 2.909, suggesting its more volatile than the S&P 500 by 190.877%.
-
Which is a Better Dividend Stock GHRS or ITRM?
GH Research PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research PLC pays -- of its earnings as a dividend. Iterum Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GHRS or ITRM?
GH Research PLC quarterly revenues are --, which are smaller than Iterum Therapeutics PLC quarterly revenues of --. GH Research PLC's net income of -$8.8M is lower than Iterum Therapeutics PLC's net income of -$6.6M. Notably, GH Research PLC's price-to-earnings ratio is -- while Iterum Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research PLC is -- versus 29.06x for Iterum Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHRSGH Research PLC-- -- -- -$8.8M ITRMIterum Therapeutics PLC29.06x -- -- -$6.6M
-
Which has Higher Returns GHRS or JAZZ?
Jazz Pharmaceuticals PLC has a net margin of -- compared to GH Research PLC's net margin of -10.31%. GH Research PLC's return on equity of -- beat Jazz Pharmaceuticals PLC's return on equity of 12.12%.
Company Gross Margin Earnings Per Share Invested Capital GHRSGH Research PLC-- -$0.17 -- JAZZJazz Pharmaceuticals PLC88.35% -$1.52 $9.5B -
What do Analysts Say About GHRS or JAZZ?
GH Research PLC has a consensus price target of $34.83, signalling upside risk potential of 235.58%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $184.00 which suggests that it could grow by 88.18%. Given that GH Research PLC has higher upside potential than Jazz Pharmaceuticals PLC, analysts believe GH Research PLC is more attractive than Jazz Pharmaceuticals PLC.
Company Buy Ratings Hold Ratings Sell Ratings GHRSGH Research PLC5 0 0 JAZZJazz Pharmaceuticals PLC10 2 0 -
Is GHRS or JAZZ More Risky?
GH Research PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.382, suggesting its less volatile than the S&P 500 by 61.836%.
-
Which is a Better Dividend Stock GHRS or JAZZ?
GH Research PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GHRS or JAZZ?
GH Research PLC quarterly revenues are --, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $897.8M. GH Research PLC's net income of -$8.8M is higher than Jazz Pharmaceuticals PLC's net income of -$92.5M. Notably, GH Research PLC's price-to-earnings ratio is -- while Jazz Pharmaceuticals PLC's PE ratio is 13.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research PLC is -- versus 1.54x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHRSGH Research PLC-- -- -- -$8.8M JAZZJazz Pharmaceuticals PLC1.54x 13.04x $897.8M -$92.5M
-
Which has Higher Returns GHRS or MNMD?
Mind Medicine has a net margin of -- compared to GH Research PLC's net margin of --. GH Research PLC's return on equity of -- beat Mind Medicine's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GHRSGH Research PLC-- -$0.17 -- MNMDMind Medicine-- -$0.35 -- -
What do Analysts Say About GHRS or MNMD?
GH Research PLC has a consensus price target of $34.83, signalling upside risk potential of 235.58%. On the other hand Mind Medicine has an analysts' consensus of $24.50 which suggests that it could grow by 298.37%. Given that Mind Medicine has higher upside potential than GH Research PLC, analysts believe Mind Medicine is more attractive than GH Research PLC.
Company Buy Ratings Hold Ratings Sell Ratings GHRSGH Research PLC5 0 0 MNMDMind Medicine7 0 0 -
Is GHRS or MNMD More Risky?
GH Research PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mind Medicine has a beta of 2.820, suggesting its more volatile than the S&P 500 by 181.968%.
-
Which is a Better Dividend Stock GHRS or MNMD?
GH Research PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mind Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research PLC pays -- of its earnings as a dividend. Mind Medicine pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GHRS or MNMD?
GH Research PLC quarterly revenues are --, which are smaller than Mind Medicine quarterly revenues of --. GH Research PLC's net income of -$8.8M is higher than Mind Medicine's net income of -$23.3M. Notably, GH Research PLC's price-to-earnings ratio is -- while Mind Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research PLC is -- versus -- for Mind Medicine. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHRSGH Research PLC-- -- -- -$8.8M MNMDMind Medicine-- -- -- -$23.3M
-
Which has Higher Returns GHRS or MURA?
Mural Oncology PLC has a net margin of -- compared to GH Research PLC's net margin of --. GH Research PLC's return on equity of -- beat Mural Oncology PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GHRSGH Research PLC-- -$0.17 -- MURAMural Oncology PLC-- -$2.01 -- -
What do Analysts Say About GHRS or MURA?
GH Research PLC has a consensus price target of $34.83, signalling upside risk potential of 235.58%. On the other hand Mural Oncology PLC has an analysts' consensus of $5.00 which suggests that it could grow by 90.11%. Given that GH Research PLC has higher upside potential than Mural Oncology PLC, analysts believe GH Research PLC is more attractive than Mural Oncology PLC.
Company Buy Ratings Hold Ratings Sell Ratings GHRSGH Research PLC5 0 0 MURAMural Oncology PLC0 2 0 -
Is GHRS or MURA More Risky?
GH Research PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Mural Oncology PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock GHRS or MURA?
GH Research PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mural Oncology PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research PLC pays -- of its earnings as a dividend. Mural Oncology PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GHRS or MURA?
GH Research PLC quarterly revenues are --, which are smaller than Mural Oncology PLC quarterly revenues of --. GH Research PLC's net income of -$8.8M is higher than Mural Oncology PLC's net income of -$34.3M. Notably, GH Research PLC's price-to-earnings ratio is -- while Mural Oncology PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research PLC is -- versus -- for Mural Oncology PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHRSGH Research PLC-- -- -- -$8.8M MURAMural Oncology PLC-- -- -- -$34.3M
-
Which has Higher Returns GHRS or PRTA?
Prothena Corp PLC has a net margin of -- compared to GH Research PLC's net margin of -2128.54%. GH Research PLC's return on equity of -- beat Prothena Corp PLC's return on equity of -21.68%.
Company Gross Margin Earnings Per Share Invested Capital GHRSGH Research PLC-- -$0.17 -- PRTAProthena Corp PLC-- -$1.12 $437.7M -
What do Analysts Say About GHRS or PRTA?
GH Research PLC has a consensus price target of $34.83, signalling upside risk potential of 235.58%. On the other hand Prothena Corp PLC has an analysts' consensus of $49.25 which suggests that it could grow by 562.85%. Given that Prothena Corp PLC has higher upside potential than GH Research PLC, analysts believe Prothena Corp PLC is more attractive than GH Research PLC.
Company Buy Ratings Hold Ratings Sell Ratings GHRSGH Research PLC5 0 0 PRTAProthena Corp PLC5 2 0 -
Is GHRS or PRTA More Risky?
GH Research PLC has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prothena Corp PLC has a beta of 0.107, suggesting its less volatile than the S&P 500 by 89.329%.
-
Which is a Better Dividend Stock GHRS or PRTA?
GH Research PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prothena Corp PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GH Research PLC pays -- of its earnings as a dividend. Prothena Corp PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GHRS or PRTA?
GH Research PLC quarterly revenues are --, which are smaller than Prothena Corp PLC quarterly revenues of $2.8M. GH Research PLC's net income of -$8.8M is higher than Prothena Corp PLC's net income of -$60.2M. Notably, GH Research PLC's price-to-earnings ratio is -- while Prothena Corp PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GH Research PLC is -- versus 2.92x for Prothena Corp PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GHRSGH Research PLC-- -- -- -$8.8M PRTAProthena Corp PLC2.92x -- $2.8M -$60.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 Recession-Proof ETFs to Invest in Now
The U.S. gross domestic product (GDP) contracted 0.3% during the…
Is Butterfly Network the Best Small-Cap Stock?
Brought to public trading by an SPAC merger in early…
Stock Ideas
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 10
Regencell Bioscience Holdings [RGC] is up 79.25% over the past day.
Buy
97
NGVC alert for May 10
Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.
Sell
38
ONTO alert for May 10
Onto Innovation [ONTO] is down 30.17% over the past day.
